SCHEMBL616092

SCHEMBL616092

Cc1nc2cc(NS(=O)(=O)c3cc(Cl)ccc3Cl)ccc2n1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
CDK1 P06493 1/20 0.53
CCNB1 P14635 1/20 0.53
CCNA2 P20248 1/20 0.53
CDK2 P24941 1/20 0.53
CDK7 P50613 1/20 0.53
CCNH P51946 1/20 0.53
CCNA1 P78396 1/20 0.53
ALDH1A1 P00352 4/20 0.52
MAPT P10636 2/20 0.52
HTT P42858 2/20 0.52
LMNA P02545 2/20 0.50
ALPL P05186 1/20 0.50
POLB P06746 2/20 0.49
TP53 P04637 2/20 0.49
MAPK1 P28482 1/20 0.49
USP2 O75604 1/20 0.48
F2 P00734 1/20 0.48
PAX8 Q06710 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618899 0.92 NPC1 (0.54) NPC1RAB9ACDK1CCNB1CCNA2
SCHEMBL616054 0.84 NPC1 (0.53) NPC1RAB9AMAPTLMNAPOLB
SCHEMBL13106696 0.79 ACLY (0.55) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL618857 0.78 LMNA (0.50) NPC1RAB9AMAPTHTTLMNA
SCHEMBL4966463 0.78 PAX8 (0.64) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL10089757 0.76 LMNA (0.64) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL616005 0.76 FBP1 (0.65) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL435075 0.76 NPC1 (0.61) NPC1RAB9AALDH1A1MAPTLMNA
SCHEMBL5348053 0.76 ALPL (0.58) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL615397 0.74 HSD11B1 (0.50) NPC1RAB9AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 NPC1 2863/4885RAB9A 4048/4885CDK1 1159/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 NPC1 2357/4885RAB9A 3099/4885CDK1 736/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 NPC1 2357/4885RAB9A 3099/4885CDK1 736/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 NPC1 1368/4885RAB9A 1545/4885CDK1 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.